Summary Table — Compounds
| Compound | Type / Mechanism | Status | Typical Dosing Pattern | Half-life | Onset Window | Highlights | Notes |
|---|
Summary Table — Popular Blends
| Blend | Components | Rationale / Use | Notes |
|---|
PK & Dosing Explorer (First-Order Accumulation)
betaJump To Compound
Mixing & Dilution Cautions
ImportantFinished, labeled products (e.g., Zepbound® tirzepatide) are formulated with specific buffers, tonicity, and sterile handling. **Do not dilute or co-mix** finished products unless the label explicitly instructs it. Stability, dosing accuracy, sterility, and immunogenicity risks increase when altering formulation.
Formulation facts (illustrative)
Tirzepatide (Zepbound®)
Bacteriostatic Water (USP)
Because Zepbound is **buffered**, adding small volumes of mildly acidic diluent won’t shift pH much — but it **will** violate labeled use, may change adsorption/aggregation behavior, and compromises sterility in a device not designed for multi-dose withdrawal. Use lower strengths or prescriber-directed compounded vials rather than ad‑hoc dilution.
Glossary & Concepts
GHRH vs GHRP (GHSR agonists)
GHRH analogs (e.g., sermorelin, CJC-1295) stimulate pituitary GH release via the GHRH receptor; GHRPs (e.g., ipamorelin) stimulate via the ghrelin receptor (GHSR). Stacking them can yield larger, more physiologic pulses.
Somatostatin negative feedback
When GH/IGF-1 rise, somatostatin increases and suppresses further GH release, putting a natural brake on short-acting GHRH analogs like sermorelin.
DAC (Drug Affinity Complex)
A modification used with CJC-1295 to bind albumin, extending half-life from minutes to days, creating a tonic GH drive rather than short pulses.
Pulsatile vs tonic exposure
Short-acting stacks (Mod‑GRF + ipamorelin) create brief GH spikes that mimic physiology; long-acting (CJC‑DAC) raises baseline exposure for convenience but may increase side-effect risk if overdone.
Incretins (GLP‑1/GIP) & Half-life
Semaglutide (~7 d), tirzepatide (~5–6 d), retatrutide (~6 d, investigational) are long-acting once‑weekly agents. Micro‑patterns mainly change peak/trough swing—total weekly mg determines average exposure.